Infectious Disease Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Infectious Disease Drugs Market is Segmented by Disease (HIV, Influenza, Hepatitis, Tuberculosis, Malaria, and Others), Treatment, and Geography

Market Snapshot

Infectious Disease Drugs Market 1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors for the growth of the infectious disease drugs market include the rising awareness activities by various government and non-profit organizations, increasing prevalence of infectious diseases, and the rising funding for the research and development.

The rising prevalence of infectious diseases is expected to boost the overall growth of the market over the forecast period. According to the World Health Organization (WHO), it is estimated that in 2018, nearly 37.9 million individuals had HIV, globally. It has been identified that most of this prevalence is in low and middle-income countries, with an estimated 66% living in Sub-Saharan Africa.

Similarly, as per the WHO’s 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016. The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases. Thus, rising cases of infectious diseases are expected to increase the demand for infectious drugs resulting in the high growth of the market.

Scope of the Report

As per the scope of this report, infectious disease are disorders caused by organisms such as bacteria, viruses, fungi or parasites and there are various categories of the drugs used in the treatment of the infectious diseases. 

By Disease
HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other
By Treatment
Antibacterial
Antiviral
Antiparasitic
Other
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Malaria Segment is Expected to Hold a Significant Market Share over the Forecast Period

The high prevalence of malaria and other infections; increasing incidence of these conditions; and rising expenditure on the prevention and diagnosis of infectious diseases are likely to be the key factors responsible for the growth of this market. According to the WHO Report, Africa has been found to have the highest rate of malaria. Therefore, between 2000 and 2015, an expansion of malaria interventions has helped to reduce malaria incidence by 37% globally, and by 42% in Africa.

There are also various initiatives focusing on disease prevention are being undertaken globally. Furthermore, the government, private, and nonprofit organizations are also focusing on increasing the management of these diseases. Hence all these factors are expected to drive the overall market growth.

Picture2.png

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest infectious disease drug market owing to the rising prevalence of infectious diseases and the presence of better healthcare infrastructure. As per the Centers for Disease Control and Prevention (CDC), in 2017, a total of 9,093 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.8 cases per 100,000 population.

Furthermore, the antibiotic prescription rate is relatively high in the United States. In addition, the trend varies significantly, based on the provider in a particular state. Also, there is a rising prevalence of HIV in the United States and there is a rise in approval for the new disease treatment which is expected to boost the growth of the market. Thus, owing to the all above mentioned factors the market is expected to witness high growth over the forecast period.

Picture13.png

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are AbbVie Inc, Boehringer Ingelheim GmbH, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, Merck & Co., Inc., Novartis AG, Pfizer Inc, Sanofi SA, and Takeda Pharmaceutical Company Limited.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Awareness Activities by Various Government and Non-profit Organizations

      2. 4.2.2 Increasing Prevalence of Infectious Diseases

      3. 4.2.3 Rising Funding for the Research and Development

    3. 4.3 Market Restraints

      1. 4.3.1 Low Penetration Rates of Diagnosis and Treatment in Developing Countries

      2. 4.3.2 Side Effects of the Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease

      1. 5.1.1 HIV

      2. 5.1.2 Influenza

      3. 5.1.3 Hepatitis

      4. 5.1.4 Tuberculosis

      5. 5.1.5 Malaria

      6. 5.1.6 Other

    2. 5.2 By Treatment

      1. 5.2.1 Antibacterial

      2. 5.2.2 Antiviral

      3. 5.2.3 Antiparasitic

      4. 5.2.4 Other

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Boehringer Ingelheim GmbH

      3. 6.1.3 Gilead Sciences, Inc.

      4. 6.1.4 GlaxoSmithKline plc

      5. 6.1.5 Janssen Pharmaceutical (Johnson & Johnson)

      6. 6.1.6 Merck & Co., Inc.

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Sanofi SA

      10. 6.1.10 Takeda Pharmaceutical Company Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Infectious Disease Drugs Market market is studied from 2018 - 2026.

The Infectious Disease Drugs Market is growing at a CAGR of 4.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

AbbVie Inc, Gilead Sciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc. are the major companies operating in Infectious Disease Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!